Payment overview · 2025
General Payments
$2,459.48
104 reported records · 29 companies
Healthcare provider profile · identity verified
Diane M Gronski, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · GLENDALE, AZ · NPI 1689624629
Verified facts
What the public records show
CMS Open Payments records show Diane M Gronski, MD received $2,459.48 in general payments during 2025 across 104 reported records.
Novo Nordisk Inc accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 397 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 480 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GENOTROPIN as an associated drug or biological on 864 records involving 515 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Genotropin by this doctor in 2024.
Sandoz Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OMNITROPE as an associated drug or biological on 65 records involving 52 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Omnitrope by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $491.96 | 20.0% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $332.88 | 13.5% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $175.42 | 7.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $174.85 | 7.1% | 6 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $162.44 | 6.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $138.99 | 5.7% | 13 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $126.42 | 5.1% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $104.12 | 4.2% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$92.90 | 3.8% | 5 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $92.03 | 3.7% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $69.85 | 2.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.21 | 2.2% | 3 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $52.74 | 2.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $49.86 | 2.0% | 2 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $41.17 | 1.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.10 | 1.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.80 | 1.2% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $28.36 | 1.1% | 1 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $27.22 | 1.1% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $24.67 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.29 | 0.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.82 | 0.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.37 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.35 | 0.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.48 | 0.7% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.33 | 0.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.13 | 0.6% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $13.98 | 0.6% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $8.74 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,266.79 | 102 |
| Consulting Fee | $175.00 | 1 |
| Education | $17.69 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $257.96 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $234.00 | 12 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $188.33 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $175.42 | 5 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $162.44 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $126.42 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $117.37 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $115.09 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $114.52 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $113.16 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $104.12 | 7 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $92.03 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $78.54 | 7 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $72.60 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $69.85 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.89 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $62.82 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.21 | 3 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $52.74 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $52.74 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $49.86 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $46.39 | 3 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $41.17 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $39.55 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $29.80 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $28.36 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $10.34 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $10.34 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $8.74 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $7.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 397 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 201 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 214 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 480 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 140 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 252 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
252 | 69 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
397 | 101 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
201 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
201 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
214 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
116 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
480 | 127 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
140 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | GENOTROPIN open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 515 recipient NPIs · example record 1228794127 |
Genotropin · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Sandoz Inc. Exact reporting entity; no affiliate inference |
2025 | OMNITROPE open payments reported associated product |
CMS Open Payments — General Payments 65 supporting records · 52 recipient NPIs · example record 1181967227 |
Omnitrope · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1357 | 378 |
| Ozempic | Semaglutide | 480 | 127 |
| Farxiga | Dapagliflozin Propanediol | 397 | 101 |
| Metformin Hcl | Metformin Hcl | 376 | 122 |
| Synthroid | Levothyroxine Sodium | 252 | 69 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 226 | 61 |
| Mounjaro | Tirzepatide | 214 | 47 |
| Jardiance | Empagliflozin | 201 | 52 |
| Liothyronine Sodium | Liothyronine Sodium | 191 | 66 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 180 | 68 |
| Pioglitazone Hcl | Pioglitazone Hcl | 175 | 52 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 173 | 59 |
| Metformin Hcl Er | Metformin Hcl | 170 | 53 |
| Glimepiride | Glimepiride | 163 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 150 | 47 |
| Tresiba Flextouch U-100 | Insulin Degludec | 150 | 37 |
| Rybelsus | Semaglutide | 140 | 30 |
| Glipizide | Glipizide | 117 | 38 |
| Trulicity | Dulaglutide | 116 | 24 |
| Alendronate Sodium | Alendronate Sodium | 106 | 36 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 25 |
| Methimazole | Methimazole | 94 | 35 |
| Novolog Flexpen | Insulin Aspart | 85 | 29 |
| Humalog Kwikpen U-100 | Insulin Lispro | 70 | 28 |
| Glipizide Er | Glipizide | 69 | 22 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 24 |
| Januvia | Sitagliptin Phosphate | 61 | 18 |
| Humalog | Insulin Lispro | 57 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 57 | 19 |
| Dexamethasone | Dexamethasone | 52 | 46 |
| Losartan Potassium | Losartan Potassium | 52 | 18 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 48 | 21 |
| Novolog | Insulin Aspart | 48 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 16 |
| Calcitriol | Calcitriol | 46 | 17 |
| Droplet Pen Needle | Pen Needle, Diabetic | 42 | 16 |
| Lisinopril | Lisinopril | 41 | 16 |
| Ezetimibe | Ezetimibe | 38 | 14 |
| Tradjenta | Linagliptin | 38 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 37 | 17 |
| Hydrocortisone | Hydrocortisone | 35 | 11 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 34 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 33 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Simvastatin | Simvastatin | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Gabapentin | Gabapentin | 24 | 14 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Levoxyl | Levothyroxine Sodium | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Unithroid | Levothyroxine Sodium | 20 | suppressed |
| Admelog Solostar | Insulin Lispro | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Genotropin | Somatropin | 17 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Omnitrope | Somatropin | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,459.48 · 104 records | Novo Nordisk Inc | AIRSUPRA, AMYVID, BREZTRI, CRYSVITA, CeQur Simplicity, Cleerly Ischemia, Cleerly Labs, EVENITY, FARXIGA, GEMTESA, INTELLIS ADAPTIVESTIM, ISTURISA, JARDIANCE, JATENZO, KISUNLA, KRYSTEXXA, Kerendia, Korlym, MINIMED 780G, MOUNJARO, MYCAPSSA, OTEZLA, Ozempic, PAXLOVID, PROCLAIM, PROLIA, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, SYNTHROID, TEPEZZA, TRELEGY ELLIPTA, TWIIST, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, WATCHMAN FLX, Wegovy, XIFAXAN, Yorvipath, ZENPEP, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error